Oś zapalna mikroglejów i śródbłonka naczyń związana z receptorem TLR4 w opornej na leki epilepsji skroniowej: zintegrowane badania transkryptomiki i genetyki
A TLR4-Associated Microglia-Endothelial Inflammatory Axis in Drug-Resistant Temporal Lobe Epilepsy: Integrated Transcriptomic and Genetic Evidence
W skrócie
Naukowcy zbadali, jak komórki mózgu zwane mikroglejami powodują zapalenie i opór na leki w epilepsji skroniowej. Odkryli, że pięć konkretnych genów reguluje komunikację między mikroglejami a ściankami naczyń krwionośnych mózgu, co przyczynia się do tego problemu. Badanie sugeruje, że leki takie jak simwastatyna mogą być przydatne w leczeniu tej postaci epilepsji, ale wynik wymaga dalszych badań.
Oryginalny abstract (angielski)
Microglia-driven neuroinflammation contributes to epileptogenesis and drug resistance in temporal lobe epilepsy (TLE), but the cellular organization of the neuroinflammatory hub and its coupling to the cerebrovascular endothelium remain unresolved. We performed a retrospective secondary analysis of publicly available datasets, integrating paired hippocampal bulk transcriptomics (GSE134697), an integrated temporal-lobe single-cell/nucleus RNA sequencing (sc/snRNA-seq) atlas (9 patients with drug-resistant TLE and 4 controls), two-sample Mendelian randomization (MR) and summary-based Mendelian randomization (SMR), and independent hippocampal ( = 77) and peripheral blood ( = 141) cohorts. Five candidate neuroimmune hub genes (, , , and ) were prioritized using a prespecified, threshold-dependent workflow and mapped to a microglia-cerebrovascular endothelium-peripheral myeloid cell axis. sc/snRNA-seq identified an activated endothelial subpopulation, detected only in TLE samples, and expansion of a microglial compartment with disease-associated microglia (DAM)-like features; CellChat and MultiNicheNet prioritized microglia-derived SPP1, C1QA and MIF as candidate mediators of endothelial inflammatory activation via S1PR1/ITGB1, CD93 and CD74. Plasma kynurenine showed a nominally significant association with focal epilepsy in MR (inverse-variance weighted [IVW] OR = 1.96, 95% CI 1.10-3.52, = 0.024), whereas SMR did not detect genetically predicted effects of or expression on focal epilepsy risk; these findings do not establish an acquired disease mechanism. A + two-gene signature showed exploratory discrimination in an independent hippocampal cohort (area under the receiver operating characteristic curve [AUC] = 0.868), and blood was selectively elevated in drug-naïve newly diagnosed patients (AUC = 0.684). Targeted gene set enrichment analysis (GSEA) and molecular docking nominated simvastatin as a repurposing candidate predicted computationally to interact with MD-2; this prediction has not been functionally validated. This multi-cohort study identifies a TLR4-associated microglia-endothelial inflammatory axis in drug-resistant TLE and generates hypotheses for prospective biomarker studies and experimental drug-repurposing research.